PYC Share PerformanceMore
|52 week high||4.3000 07/09/16|
|52 week low||0.9340 17/07/17|
|52 week change||-2.1250 (-65.38%)|
|4 week volume||4,503,821 23/07/17|
Latest News« previous» nextMore
31/07/2017 - 07:30 StockMarketWire
Physiomics signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating...
31/07/2017 - 07:00 RNS
Statement regarding a contract entered into/awarded/signed
06/06/2017 - 07:00 RNS
24/05/2017 - 07:00 RNS
05/05/2017 - 07:00 RNS
Miscellaneous medium priority announcements
24/03/2017 - 15:05 StockMarketWire
Physiomics has reported an operating loss of 263,509 for the six month period ended 31 December, compared to a restated lo...
24/03/2017 - 12:15 RNS
Announcement of half-year/second quarter financial results
11/01/2017 - 08:51 StockMarketWire
Physiomics anticipates that in H1 of its current financial year revenues will be broadly in line with the comparable period...
|Dividend yield||0 %|
Equity Research (PYC)
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients...
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives...
Following the decision not to proceed with the acquisition of oncology therapeutics Company BioMoti, Physiomics is now 100% focused on growing the revenues and creating a path to profitability in the...
Latest discussion posts More
“Just peace meal work.. Nothing revolutionary!”▼
“Don't buy, ok....”▼
Codes & Symbols
|Symbols||PYC, LSE:PYC, PYC.L, PYC:LN, LON:PYC, XLON:PYC|